Cancer Therapeutics CRC preclinical data

In a mouse model of breast cancer, CTx-0294886 plus Avastin bevacizumab significantly increased median survival time vs. Avastin alone (p=0.02). Additionally, CTx-0294886 plus Avastin inhibited angio...